Dr. Ajazuddin Z. Shaikh, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 611 E Douglas Rd, Ste 208, Mishawaka, IN 46545 Phone: 574-232-5928 Fax: 574-232-4888 |
Dr. William S. Sarnat, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 611 E Douglas Rd, Ste 208, Mishawaka, IN 46545 Phone: 574-232-5928 Fax: 574-232-4888 |
Dr. Ashfaq A Turk, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 611 E Douglas Rd, Ste 208, Mishawaka, IN 46545 Phone: 574-232-5928 Fax: 574-232-4888 |
Dr. Sachin R. Patel, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 611 E Douglas Rd Ste 208, Mishawaka, IN 46545 Phone: 574-335-6700 Fax: 574-335-0726 |
News Archive
Researchers may be one step closer to better understanding how anesthesia works. A study in the August issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists- (ASA-), found stimulating a major dopamine-producing region in the brain, the ventral tegmental area (VTA), caused rats to wake from general anesthesia, suggesting that this region plays a key role in restoring consciousness after general anesthesia.
Nobilon, the human vaccine business unit of Schering-Plough Corporation has announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.
Mylan Inc. today commented on a ruling for partial summary judgment in its patent infringement lawsuit against Sunovion Pharmaceuticals Inc. in relation to Sunovion's Brovana product.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced the initiation of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of Z944, a novel oral T-type calcium channel blocker with demonstrated preclinical potential for the treatment of acute and inflammatory pain.
› Verified 9 days ago